Think Weed Is Harmless? This Study Might Change Your Mind
Published in the journal Heart, CNN reported that the analysis pooled medical data from over 200 million people, most between the ages of 19 and 59. It found that marijuana users had a 29 percent higher risk of heart attacks and a 20 percent higher risk of strokes compared to nonusers.
The most concerning finding? These risks were seen in young, otherwise healthy individuals with no prior heart conditions.
"What was particularly striking was that the concerned patients hospitalized for these disorders were young," said senior study author Émilie Jouanjus, a pharmacology professor at the University of Toulouse.
That ruled out tobacco or existing cardiovascular problems as the primary cause.
This is one of the largest studies to date linking cannabis use with cardiovascular disease, and its timing is critical. As marijuana legalization expands, use has surged past that of tobacco in some demographics.
Many believe marijuana is a safer, more natural alternative to smoking. Experts say that perception needs to change—fast.
"Clinicians need to screen people for cannabis use and educate them about its harms, the same way we do for tobacco," said Dr. Lynn Silver of the University of California, San Francisco. Silver co-authored an editorial accompanying the study, calling for urgent updates to how marijuana is regulated and discussed publicly.
The risks don't stop at inhalation. One recent study found that THC-laced edibles can impair vascular function just as much—or more—than smoking. In that study, vascular function dropped 42 percent in marijuana smokers and 56 percent in edible users.
And the potency? It's not 1970 anymore. Today's cannabis is up to 510 times stronger than the joints of decades past, with some concentrates reaching 99 percent pure THC. That's raising alarms about addiction, psychosis, and now, potentially fatal heart problems.
"If I was a 60-year-old with cardiovascular risk, I'd be very cautious," Silver warned.
Think Weed Is Harmless? This Study Might Change Your Mind first appeared on Men's Journal on Jun 18, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Nyxoah Reports Second Quarter Financial and Operating Results
REGULATED INFORMATION Nyxoah Reports Second Quarter Financial and Operating ResultsFDA Approves Genio® System for U.S. Market; Company Begins Commercial Launch Mont-Saint-Guibert, Belgium – August 18, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ('Nyxoah' or the 'Company'), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the second quarter of 2025. Recent Financial and Operating Highlights Received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for the Genio system, the first and only bilateral hypoglossal neurostimulation therapy approved in the U.S. Kicked off the U.S. commercial launch of the Genio system DREAM pivotal study data published in the Journal of Clinical Sleep Medicine Revenue for the second quarter of 2025 was €1.3 million, compared to €0.8 million in the second quarter of 2024, representing 74% year over year growth Cash, cash equivalents and financial assets were €43.0 million at June 30, 2025, compared to €63.0 million at the end of March 31, 2025. "This FDA approval represents a historic milestone for Nyxoah and marks the beginning of what we expect to be a transformational period for our company," commented Olivier Taelman, Nyxoah's Chief Executive Officer. "Genio is now the first and only bilateral hypoglossal neurostimulation therapy approved in the United States, offering a truly differentiated solution for OSA patients who have been underserved by existing therapies. Our world-class commercial team is in place, and we have begun to execute on our commercial strategy.' FDA PMA Approval As previously disclosed, on August 8, 2025, the Company received FDA PMA for its Genio system, marking a historic milestone for Nyxoah. Genio's unique design utilizes bilateral stimulation, and offers patients a leadless, full-body 1.5T and 3T MRI compatible, non-implanted battery solution, powered and controlled by a wearable component. The Genio system's FDA approval was supported by the high-quality, differentiated safety and efficacy data from the Company's DREAM pivotal trial, which demonstrated that Genio is efficacious regardless of a patient's sleeping position. This is a critical differentiator as on average, people sleep in a supine position between 35% and 40% of the night. The DREAM study measured position-specific outcomes and demonstrated a 66.6% median AHI reduction while patients slept in a supine position despite the fact that the number of airway obstructions can double in this position. This reduction compares favorably to the 71.0% reduction in AHI shown while patients slept in a non-supine position. CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS (unaudited)(in thousands) For the three months ended June 30 For the six months ended June 30 2025 2024 2025 2024 Revenue 1 340 771 2 404 1 992 Cost of goods sold ( 490) ( 281) ( 896) ( 735) Gross profit € 850 € 490 € 1 508 € 1 257 Research and Development Expense (10 059) (7 472) (19 048) (14 671) Selling, General and Administrative Expense (10 672) (6 383) (23 063) (12 355) Other income 31 58 115 249 Operating loss for the period € (19 850) € (13 307) € (40 488) € (25520) Financial income 2 858 2 069 5 480 3 477 Financial expense (3 337) (1 445) (7 579) (2 436) Loss for the period before taxes € (20 329) € (12 683) € (42 587) € (24479) Income taxes ( 278) ( 441) ( 404) ( 551) Loss for the period € (20 607) € (13 124) € (42 991) € (25030) Loss attributable to equity holders € (20 607) € (13 124) € (42 991) € (25030) Other comprehensive loss Items that may be subsequently reclassified to profit or loss (net of tax) Currency translation differences 232 ( 82) 230 ( 22) Total comprehensive loss for the year, net of tax € (20 375) € (13 206) € (42 761) € (25052) Loss attributable to equity holders € (20 375) € (13 206) € (42 761) € (25052) Basic Loss Per Share (in EUR) € (0.551) € (0.428) € (1.149) € (0.843) Diluted Loss Per Share (in EUR) € (0.551) € (0.428) € (1.149) € (0.843) CONSOLIDATED STATEMENT OF FINANCIAL POSITION (unaudited) (in thousands) As at June 302025 December 31 2024 ASSETS Non-current assets Property, plant and equipment 5 015 4 753 Intangible assets 51 407 50 381 Right of use assets 3 059 3 496 Deferred tax asset 76 76 Other long-term receivables 1 799 1 617 € 61 356 € 60 323 Current assets Inventory 5 332 4 716 Trade receivables 1 330 3 382 Contract assets 1 508 − Other receivables 3 014 2 774 Other current assets 944 1 656 Financial assets 20 257 51 369 Cash and cash equivalents 22 729 34 186 € 55 114 € 98 083 Total assets € 116 470 € 158 406 EQUITY AND LIABILITIES Share capital and reserves Share capital 6 431 6 430 Share premium 314 388 314 345 Share based payment reserve 11 645 9 300 Other comprehensive income 1 144 914 Retained loss (260 211) (217 735) Total equity attributable to shareholders € 73 397 € 113 254 LIABILITIES Non-current liabilities Financial debt 18 928 18 725 Lease liability 2 157 2 562 Provisions 404 1 000 Deferred tax liability 34 19 Contract liability 225 472 Other liability 379 845 € 22 127 € 23 623 Current liabilities Financial debt 246 248 Lease liability 1 071 1 118 Trade payables 9 408 9 505 Current tax liability 3 990 4 317 Contract liability 460 117 Other liability 5 771 6 224 € 20 946 € 21 529 Total liabilities € 43 073 € 45 152 Total equity and liabilities € 116 470 € 158 406 RevenueRevenue was €1.3 million for the second quarter ending June 30, 2025, compared to €0.8 million for the second quarter ending June 30, 2024, representing a 74% year over year increase. Cost of Goods SoldCost of goods sold was €490,000 for the second quarter ending June 30, 2025, representing a gross profit of €0.9 million, or gross margin of 63.4%. This compares to cost of goods sold of €281,000 in the second quarter ending June 30, 2024, for a gross profit of €0.5 million, or gross margin of 63.6%. Research and DevelopmentFor the second quarter ending June 30, 2025, research and development ('R&D') expenses were €10.0 million, versus €7.5 million for the second quarter ending June 30, 2024. The increase in research and development expenses was primarily due to higher R&D activities offset by a decrease in clinical study expenses. Selling, General and AdministrativeFor the second quarter ending June 30, 2025, selling, general and administrative expenses were €10.7 million, versus €6.4 million for the second quarter ending June 30, 2024. The increase in selling, general and administrative expenses was primarily due to an increase in costs to support the commercialization of Genio system, including the Company's overall scale-up preparations for the commercialization of Genio system in the US in connection with the receipt of FDA approval. Operating LossTotal operating loss for the second quarter ending June 30, 2025 was €19.9 million, versus €13.3 million in the second quarter 2024, respectively. This was driven by an increase in selling, general and administrative expenses to support commercialization of the Genio system, including the Company's overall scale-up preparations for the commercialization of Genio system in the US in connection with the receipt of FDA approval, and increased R&D activities offset by a decrease in clinical study expenses. Cash PositionAs of June 30, 2025, cash, cash equivalents and financial assets totaled €43.0 million, compared to €63.0 million at the end of March 31, 2025. The Company also has a term debt facility with €27.5 million of remaining availability which can be drawn down in two equal tranches subject to revenue and other financial milestones. Second Quarter 2025Nyxoah's financial report for the second quarter of 2025, including details of the consolidated results, are available on the investor page of Nyxoah's website ( Conference call and webcast presentation Company management will host a conference call to discuss financial results on Monday, August 18, 2025, beginning at 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q2 2025 Earnings Call Webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the following link: Events | Nyxoah Investors required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call. The archived webcast will be available for replay shortly after the close of the call. About Nyxoah Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah's lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors' therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65. For more information, please visit Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device. Forward-looking statements Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah's goals with respect to the potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the 'Risk Factors' section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on March 20, 2025 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward- looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. Contacts: NyxoahJohn Landry, CFOIR@ For MediaIn United StatesFINN Partners – Glenn For MediaBelgium/FranceBackstage Communication – Gunther De Backergunther@ International/GermanyMC Services – Anne Henneckenyxoah@ Attachment ENGLISH_Q2 2025 Earnings PR_FINAL
Yahoo
2 hours ago
- Yahoo
Hubble telescope uncovers rare star born from cosmic collision: 'A very different history from what we would have guessed'
When you buy through links on our articles, Future and its syndication partners may earn a commission. Astronomers using the Hubble Space Telescope have discovered that a seemingly ordinary white dwarf star is actually the result of a dramatic stellar merger. This result, detailed in a new study led by Snehalata Sahu and Boris Gaensicke of the University of Warwick in the U.K., suggests that other "normal-looking" white dwarfs scattered throughout the universe could also have violent pasts. "It's a discovery that underlines things may be different from what they appear to us at first glance," Gaensicke, study co-author and a professor of physics at the University of Warwick who serves as the principal investigator of the Hubble program, said in a statement. "Until now, this appeared as a normal white dwarf, but Hubble's ultraviolet vision revealed that it had a very different history from what we would have guessed." The star, named WD 0525+526, is located about 128 light-years from Earth. Though it appeared rather standard at first glance through visible light, further observations using the Hubble telescope revealed telltale signs of a more turbulent origin, the new study reports. White dwarfs are the dense remnants of stars like our sun that have exhausted their fuel supplies and collapsed into Earth-size objects. Despite their small size, however, they can pack in up to 1.4 times the mass of the sun. Most white dwarfs form from the predictable evolution of single stars nearing the final days of their life cycles, which is a path our own sun is expected to follow in about 5 billion years. However, WD 0525+526 may have followed a very different path. Instead of forming from one dying star, it appears to have emerged from the violent collision and merger of two stars. This dramatic past, the new study says, left subtle but detectable fingerprints in the white dwarf's atmospheric makeup. When Gaensicke and his team examined WD 0525+526 with Hubble's ultraviolet instruments, they detected an unusual amount of carbon in the star's atmosphere — a key sign the star was formed in a merger. Typically, white dwarfs have outer layers of hydrogen and helium that obscure their carbon-rich cores. But in mergers such as this one, the intense collision can strip away much of these outer layers, allowing carbon to rise to the surface. The signals of such stars are difficult to detect in visible light, but become clearer in ultraviolet wavelengths — and that's where Hubble excels. WD 0525+526 is remarkable even among the small number of white dwarfs known to be merger remnants, according to the statement. It has a surface temperature of nearly 21,000 Kelvin (about 37,000 degrees Fahrenheit) and a mass 1.2 times that of the sun, making it both hotter and more massive than others in this rare category, the study notes. Because WD 0525+526 appeared completely normal in visible light, astronomers now suspect that many more white dwarfs could be hiding similar explosive origins. "We would like to extend our research on this topic by exploring how common carbon white dwarfs are among similar white dwarfs, and how many stellar mergers are hiding among the normal white dwarf family," Antoine Bedrad, a researcher at the University of Warwick who co-led the study, said in the statement. RELATED STORIES: — White dwarfs: Facts about the dense stellar remnants — White dwarfs are 'heavy metal' zombie stars endlessly cannibalizing their dead planetary systems — What is dark energy? Exploding white dwarf stars may help us crack the case "That will be an important contribution to our understanding of white dwarf binaries, and the pathways to supernova explosions." This research is described in a paper published Aug. 6 in the journal Nature Astronomy.
Bloomberg
3 hours ago
- Bloomberg
Geopolitics in Spotlight Ahead of Retail Earnings, Jackson Hole
Get a jump start on the US trading day with Matt Miller and Katie Greifeld on "Bloomberg Open Interest." Ukrainian President Volodymyr Zelenskiy and his European allies meet President Trump in Washington today. Retail earnings this week will shed light on the health of US consumers. Novo Nordisk is slashing the cost of Ozempic for cash-paying patients to $499 a month and partnering with GoodRx to offer it at the same price at US pharmacies. GoodRx CEO talks to Open Interest about offering the best prices on drugs to consumers. (Source: Bloomberg)
